Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes

Oculis Holding Ag (OCS) announced an update on their ongoing clinical study.

The Phase 3 study “A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in Subjects With Diabetic Macular Edema” tests Oculis’ eye drop OCS-01 in diabetic macular edema. It aims to show that a simple, topical treatment can safely improve vision, which could reshape care and expand the addressable market.

OCS-01 is a steroid eye drop (dexamethasone 1.5%) designed to reduce swelling in the retina caused by diabetes. It is given as frequent drops at first, then at a lower dose for maintenance, and is compared with a placebo “vehicle” drop with no active drug.

The trial is interventional and randomized, so patients are assigned by chance to OCS-01 or placebo. It is double-masked, meaning both patients and doctors do not know who gets which treatment, and the main goal is to test whether the drug works and is safe as a treatment.

The study was first submitted in Dec. 2023, marking the formal start of regulatory tracking. It is now listed as completed, and the last update on Apr. 30, 2026 signals that Oculis has locked key data and may be preparing for deeper analysis or discussions with regulators.

For investors, completion of this pivotal trial is a major catalyst for Oculis stock (OCS) because positive Phase 3 data can support approval and commercial rollout. Success would position Oculis against current injectable therapies, potentially capturing patients who want a non-invasive option and raising expectations for market share and partnerships.

For the wider eye-care market, a validated eye drop for diabetic macular edema could pressure incumbents focused on injections, including large ophthalmology players. Sentiment may shift toward platform eye-drop technology, and investors will watch closely for any readthrough to similar pipeline assets and competitive responses.

This OCS-01 study is now completed and recently updated, with further details and any forthcoming results to be made available on the ClinicalTrials portal.

To learn more about OCS’s potential, visit the Oculis Holding Ag drug pipeline page.